Abstracts tagged "Osteitis"

Abstract Number: 1248 • 2019 ACR/ARP Annual Meeting
Clinical Manifestations and Management of US Patients with SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) Syndrome, a Retrospective Study
Delamo Bekele¹, Paras Karmacharya ², Kerry Wright ² and Clement Michet ¹, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: The SAPHO syndrome is a rare inflammatory disorder of bones, joints and skin first coined by Chamot in 1987 characterized by synovitis, acne, pustulosis,…
Abstract Number: 514 • 2015 ACR/ARHP Annual Meeting
MRI Bone Oedema at Enrollment Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort
Yoshikazu Nakashima¹, Mami Tamai², Toru Michitsuji³, Toshimasa Shimizu², Shoichi Fukui⁴, Masataka Umeda¹, Ayako Nishino¹, Tomohiro Koga³, Shin-ya Kawashiri⁵, Naoki Iwamoto², Kunihiro Ichinose², Yasuko Hirai⁴, Hideki Nakamura⁴, Tomoki Origuchi⁶ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ⁴Nagasaki University, Nagasaki, Japan, ⁵Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁶Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: To clarify whether MRI bone oedema predicts the development of rapid radiographic progression (RRP) in Nagasaki University Early Arthritis Cohort patients with early-stage rheumatoid…
Abstract Number: 2732 • 2015 ACR/ARHP Annual Meeting
The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective
Norman B. Gaylis¹, Steven Needell² and Joanne Sagliani¹, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Boca Radiology Group, Boca Raton, FL
Background/Purpose: Although adrenocorticotropin (ACTH) gel was approved by the FDA for the treatment of RA in 1952, data on its clinical and structural benefits for…
Abstract Number: 2389 • 2014 ACR/ARHP Annual Meeting
MRI Osteitis at Baseline Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis
Yoshikazu Nakashima¹, Mami Tamai², Junko Kita³, Sousuke Tsuji¹, Shoichi Fukui¹, Masataka Umeda¹, Ayako Nishino¹, Takahisa Suzuki¹, Yoshiro Horai¹, Akitomo Okada⁴, Tomohiro Koga¹, Shinya Kawashiri⁵, Naoki Iwamoto¹, Kunihiro Ichinose¹, Yasuko Hirai¹, Kazuhiko Arima⁵, Hideki Nakamura¹, Tomoki Origuchi⁶, Masataka Uetani⁷, Kiyoshi Aoyagi⁵, Katsumi Eguchi⁸ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁵Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Sasebo City General Hospital, Sasebo, Japan
Background/Purpose: EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis (RA) states that magnetic resonance imaging (MRI)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].